Ohio State Cancer Research Played a Significant Role in FDA Approval of Important New CLL Drug

February 14, 2014

COLUMBUS, Ohio – On Feb. 12, 2014, the U.S. Food and Drug Administration expanded the approved use​ of the drug ibrutinib to chronic lymphocytic leukemia (CLL).

Much of the clinical and basic-science research that led to the approval of ibrutinib for CLL was performed by scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Ibrutinib (Imbruvica®) is the first drug designed to target Bruton’s tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL, the most common form of leukemia, causes a gradual increase in white blood cells called B lymphocytes, or B cells. The National Cancer Institute estimates that 15,680 Americans were diagnosed with CLL and 4,580 died from the disease in 2013.

Much of the Ohio State work was led by John C. Byrd, MD, director, division of hematology, and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC – James. Byrd also directs the OSUCCC – James CLL Experimental Therapeutics Laboratory and co-directs the Leukemia Research Program. Other key team members include Amy J Johnson, PhD, Jason Dubovsky, PhD, Jeffrey Jones, MD, MPH, Joseph Flynn, DO, MPH, Jennifer Woyach, MD, Kami Maddocks, MD, and Kristie Blum, MD.

“Our clinical studies consistently suggested that ibrutinib is a highly active oral therapeutic that produces a high rate of durable remissions – the remissions last months on end – with acceptable toxicity in relapsed and refractory CLL,” says Byrd, holder of the D. Warren Brown Designated Chair in Leukemia Research.

“Patient responses can last for many months, in part because patients are willing to remain on the drug since the side effects are very tolerable,” Byrd says.

Studies of ibrutinib by OSUCCC – James researchers include:

The FDA granted accelerated approval to ibrutinib for the treatment of mantle cell lymphoma in November 2013.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.

###

A high quality JPEG of John C. Byrd, MD, is available here.

Illustration of how ibrutinib works, Frontiers, winter 2013, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Written by Darrell E. Ward, Wexner Medical Center Public Affairs and Media Relations,614-293-3737, or Darrell.Ward@osumc.edu.

Media Contact: Amanda J. Harper, OSUCCC-James Director of Media Relations, 614-685-5420 (direct), 614-293-3737 (central line) or Amanda.Harper2@osumc.edu​.

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

New Procedures at The James Ease Lymphedema's Pain

On this week’s Toward a Cancer-Free World, nationally acclaimed Plastic & Reconstructive Surgeon Dr. Roman Skoracki explains how two brand new procedures now available at The James can help stop...

Read More

Prostate Cancer Androgen Receptor Activates a Different Gene Set When Bound to Antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by...

Read More